ANAltair Pereira de Melo Neto

Altair Pereira de Melo Neto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Altair Pereira de Melo Neto has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis

    by Marcela da Silva Kazitani Cunha, Hilária Saugo Faria, Lucas Mendes Barbosa, Leonardo Reischoffer Do Nascimento, Carlos Henrique de Oliveira Ferreira, Karlos Daniell Araújo dos Santos, Lucas Cael Azevedo Ramos Bendaham, Acza Kalica Buarque da Silva, Altair Pereira de Melo Neto, Wellgner Fernandes Oliveira Amador, et al.

    Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.

  • Efficacy and safety of mepolizumab for eosinophilic chronic obstructive pulmonary disease: A systematic review and meta-analysis

    by Milene Vitória Sampaio Sobral, Wellgner Fernandes Oliveira Amador, Altair Pereira de Melo Neto, Rafaela da Cunha Pirolla, Rodrigo Bettanim Menechini


  • Effect of Diabetes Mellitus on Clinical Outcomes After Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta‐Analysis

    by Roberta Andreucci Pereira Gomes, Ricardo Fonseca Oliveira Suruagy Motta, Evandro Martins Filho, Lidia Cheidde, Karlos Daniell Araújo Dos Santos, João Victor Androlage Assumpção, Lorenzo Furlan Anselmi, Altair Pereira de Melo Neto, Alexandre Negrao Pantaleao, Khaled M. Harmouch, et al.

    Transcatheter Aortic Valve Implantation (TAVI) or Replacement (TARV) is a widely established treatment for symptomatic severe aortic stenosis (AS) in patients with high or intermediate surgical risk. Diabetes mellitus (DM) is prevalent in TAVR patients and is associated with an increased risk of cardiovascular events, which may elevate procedural risks. A systematic review and meta‐analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Cochrane databases were searched. A random‐effects model was applied, with 95% confidence intervals (CIs) and a 5% significance level. Statistical analyses were performed using RStudio version 4.4.1. Twelve studies with 214,444 patients were included, comprising 74,294 diabetic and 140,150 nondiabetic individuals. The analysis revealed no significant differences in all‐cause mortality, procedure mortality, 30‐day mortality, or complications such as bleeding, myocardial infarction, and major complications. However, 1‐year mortality was significantly higher in the diabetic group (RR: 1.51, 95% CI: 1.08–2.13). Diabetic patients were at higher risk for renal injury (RR: 1.46, 95% CI: 1.40–1.51) and lower risk of stroke (RR: 0.91, 95% CI: 0.83–0.99). The length of hospital stay and other major complications showed no significant differences. There was an increased risk of 1‐year mortality and renal injury in diabetic patients undergoing TAVI compared to non‐diabetics. Surprisingly, the risk for developing stroke in the diabetic group was significantly lower. In any case, the study emphasizes the need for tighter DM control to decrease the risk of such complications in the future.


  • Open Access

    Respiratory outcomes of adrenergic beta-antagonists in patients undergoing tracheal extubation: a systematic review and meta-analysis of randomized controlled trials

    by Lucas Cael Azevedo Ramos Bendaham, Altair Pereira de Melo Neto, Hilária Saugo Faria, André Richard da Silva Oliveira Filho, Carlos Henrique de Oliveira Ferreira, Marcela da Silva Kazitani Cunha, Victor Gonçalves Soares, Ocílio Ribeiro Gonçalves, Milene Vitória Sampaio Sobral, Mohamed Doma, et al.

  • Open Access

    Corticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis

    by Elizabeth Honorato de Farias, Anderson Matheus Pereira da Silva, Karlos Daniell Araújo dos Santos, Altair Pereira de Melo Neto, Aishwarya Koppanatham, Júlia Cappi Aguiar Moraes Souza, Niels Pacheco-Barrios, Gabrielle de Souza Rocha, Gustavo Sousa Noleto

    Although it is known that the most commonly used therapies for West syndrome (WS) are intramuscular adrenocorticotropic hormone (ACTH) and oral prednisolone, there is still controversy in the literature regarding the equivalence of their effects.We aimed to present an updated review comparing the therapeutic and adverse effects of ACTH therapy versus corticosteroids in children with West syndrome (WS).The PubMed, EMBASE, and Cochrane Central databases were searched. The outcomes of interest selected were spasm cessation on day 14 of therapy, cessation of hypsarrhythmia and adverse effects such as weight gain, infection, irritability, and hypertension. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed. We compared the results using the risk ratio (RR) and odds ratio (OR). for the binary outcomes, with 95% confidence intervals (CI) and a random-effects model. Statistical analysis was performed using RevMan 5.1.7.Compared with corticoids, ACTH was associated with a significant increase in weight (RR: 1.41; 95% CI: 1.01–1.97; p = 0.04). There was no significant difference in cessation of spasms on day 14 (OR: 0.91; 95% CI: 0.47–1.47; p = 0.79), hypsarrhythmia (OR: 0.97; 95% CI: 0.22–4.34), irritability (RR: 0.78; 95% CI: 0.30–1.99), hypertension (RR: 0.64; 95% CI: 0.35–1.15; p = 0.14), and infection (RR: 0.69; 95% CI: 0.19–2.50; p = 0.57).This study provides robust evidence regarding the safety and efficacy of ACTH or corticoids in children with WS. However, the significant heterogeneity between studies restricts the analysis, emphasizing the need for additional research to assess the best WS treatment option.